专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06649780B1 Cationic lipids 失效
标题翻译：阳离子脂质
公开(公告)号：US06649780B1
公开(公告)日：2003-11-18
申请号：US09465562
申请日：1999-12-17
申请人： Hansjörg Eibl , Jinkang Wang , Yi Lin Zhang
发明人： Hansjörg Eibl , Jinkang Wang , Yi Lin Zhang
IPC分类号： C04C1403
CPC分类号： C07C219/06 , C07C219/08
摘要： Cationic lipids are provided which are useful in the preparation of liposomes and other lipid vesicle carriers. The lipids of the invention are particularly useful as carriers of nucleic acids and other negatively charged substances, for delivery to cells.
摘要翻译：提供了可用于制备脂质体和其他脂质囊泡载体的阳离子脂质。本发明的脂质特别可用作核酸和其它带负电荷物质的载体，用于递送至细胞。

2. 发明授权

US08273727B2 Lipid-analogous phosphoric triesters 有权
标题翻译：脂质类似磷酸三酯
公开(公告)号：US08273727B2
公开(公告)日：2012-09-25
申请号：US12552799
申请日：2009-09-02
申请人： Hansjörg Eibl
发明人： Hansjörg Eibl
IPC分类号： A61K9/127 , A61K31/66 , C07F9/02
CPC分类号： C07J51/00 , C07F9/10
摘要： The present invention relates to novel phosphoric triesters which comprise apolar lipid structures.
摘要翻译：本发明涉及包含非极性脂质结构的新型磷酸三酯。

3. 发明授权

US06506393B2 Methods of treating protozoal diseases 有权
标题翻译：治疗原生动物疾病的方法
公开(公告)号：US06506393B2
公开(公告)日：2003-01-14
申请号：US09799505
申请日：2001-03-07
申请人： Hansjörg Eibl , Clemens Unger , Jürgen Engel
发明人： Hansjörg Eibl , Clemens Unger , Jürgen Engel
IPC分类号： A61K600
CPC分类号： A61K31/685 , Y02A50/409 , Y02A50/411 , Y10S514/859 , Y10S514/928 , A61K2300/00
摘要： The invention concerns a new pharmaceutical agent for oral or topical administration in the treatment of protozoal diseases, in particular of leishmaniasis, which contains as the active substance one or several compounds having the general formula I in which R1 is a saturated or monounsaturated or polyunsaturated hydrocarbon residue with 12 to 20 C atoms and R2, R3 and R4 denote independently of one another hydrogen, a C1-C5 alkyl group, a C3-C6 cycloalkyl group or a C1-C5 hydroxyalkyl group whereby two of the residues R2, R3 and R4 can together form a C2-C5 alkylene group which, if desired, can be substituted with an —O—, —S— or NR5 group, in which R5 is hydrogen, a C1-C5 alkyl group, a C3-C6 cycloalkyl group or a C1-C5 hydroxyalkyl group as well as, if desired the usual pharmaceutical auxiliary, diluting, carrier or/and filling substances.
摘要翻译：本发明涉及用于治疗原生动物疾病，特别是利什曼病的新的药物，其含有作为活性物质的一种或几种具有通式Iin的化合物，其中R 1是饱和或不饱和或多不饱和烃残基具有12至20个C原子且R 2，R 3和R 4彼此独立地表示氢，C 1 -C 5烷基，C 3 -C 6环烷基或C 1 -C 5羟烷基，其中残基R 2，R 3和R 4中的两个可以一起形成C 2 -C 5亚烷基，如果需要，其可以被-O - ， - S-或NR 5基团取代，其中R 5是氢，C 1 -C 5烷基，C 3 -C 6环烷基或 C1-C5羟烷基，以及如果需要，通常的药物辅助剂，稀释剂，载体或/和填充物质。

4. 发明授权

US08828972B2 Formulations containing alkylphosphocholines using novel negative charge carriers 有权
标题翻译：使用新型负电荷载体的含有烷基磷酸胆碱的制剂
公开(公告)号：US08828972B2
公开(公告)日：2014-09-09
申请号：US11577518
申请日：2005-10-19
申请人： Hansjörg Eibl , Susanne Christine Wieland-Berghausen , Jean Steffan
发明人： Hansjörg Eibl , Susanne Christine Wieland-Berghausen , Jean Steffan
IPC分类号： A61K47/28 , A61K31/201 , A61K31/685 , A61K9/127 , C07F9/09 , C07F9/10 , A61K47/12 , A61K47/18 , A61K47/24
CPC分类号： A61K9/1272 , A61K31/201 , A61K31/685 , A61K47/12 , A61K47/18 , A61K47/24 , A61K47/28 , C07F9/091 , C07F9/10 , Y02A50/402 , Y02A50/409 , Y02A50/491
摘要： The invention relates to novel medicament formulations containing, as active ingredients, alkylphosphocholines and the like, alkyl-alkanediol-phosphocholines and the like, and (ether)lysolecithins and the like, in different forms of embodiment. The active ingredients are integral constituents of liposomes, also containing cholesterol and the like and a negative charge carrier. The medicament formulations are especially suitable for the treatment and/or prophylaxis of cancer, protozoan diseases such as leishmaniasis and amoebic diseases, acariasis and diseases caused by arthropods, and bacterial diseases, such as ehrlichiosis. Ocular diseases accompanied by uncontrolled cellular processes can also be advantageously influenced.
摘要翻译：本发明涉及以不同形式的实施方式含有作为活性成分的烷基磷酰胆碱等烷基链烷二醇 - 磷酸胆碱等的新型药物制剂和（醚）溶血卵磷脂等。活性成分是还含有胆固醇等脂质体和负电荷载体的组成成分。药物制剂特别适用于治疗和/或预防癌症，原生动物疾病如利什曼病和阿米巴病，疟原虫和由节肢动物引起的疾病，以及细菌性疾病，例如肝硬化。伴随着不受控制的细胞过程的眼部疾病也可以受到有利的影响。

5. 发明授权

US09326989B2 Oleyl phosphocholine 有权
标题翻译：油基磷酸胆碱
公开(公告)号：US09326989B2
公开(公告)日：2016-05-03
申请号：US12593336
申请日：2008-03-26
申请人： Hansjörg Eibl
发明人： Hansjörg Eibl
IPC分类号： A61K31/685 , A61K45/06
CPC分类号： A61K31/685 , A61K45/06 , Y02A50/402 , Y02A50/409 , Y02A50/411 , Y02A50/415
摘要： The invention relates to the use of oleyl phosphocholine and oleyl-phospho-(N.N.-dimethyl-N-ethyl)-ethyl-ammonium for the long-term and continuous treatment of serious illnesses, such as cancer, leishmaniasis, ehrlichiosis, multiple sclerosis and psoriasis, in addition to other indications mentioned in the application.
摘要翻译：本发明涉及油基磷酸胆碱和油基 - 磷酸 - （NN-二甲基-N-乙基） - 乙基铵用于长期和连续治疗严重疾病如癌症，利什曼病，埃里病，多发性硬化和银屑病，除了在应用程序中提到的其他指示。

6. 发明申请

US20100144676A1 OLEYL PHOSPHOCHOLINE 有权
公开(公告)号：US20100144676A1
公开(公告)日：2010-06-10
申请号：US12593336
申请日：2008-03-26
申请人： Hansjörg Eibl
发明人： Hansjörg Eibl
IPC分类号： A61K31/661 , A61P33/02 , A61P31/04 , A61P17/06 , A61P35/00 , A61P25/28 , A61P27/02 , C07F9/09
CPC分类号： A61K31/685 , A61K45/06 , Y02A50/402 , Y02A50/409 , Y02A50/411 , Y02A50/415
摘要： The invention relates to the use of oleyl phosphocholine and oleyl-phospho-(N.N.-dimethyl-N-ethyl)-ethyl-ammonium for the long-term and continuous treatment of serious illnesses, such as cancer, leishmaniasis, ehrlichiosis, multiple sclerosis and psoriasis, in addition to other indications mentioned in the application.
摘要翻译：本发明涉及油基磷酸胆碱和油基 - 磷酸 - （NN-二甲基-N-乙基） - 乙基铵用于长期和连续治疗严重疾病如癌症，利什曼病，埃里病，多发性硬化和银屑病，除了在应用程序中提到的其他指示。

7. 发明申请

US20120027812A1 INTRAOCULAR LENSES TREATED WITH ALKYLPHOSPHOCHOLINES FOR PHARMACOLOGICAL AFTERCATARACT PROPHYLAXIS 审中-公开
标题翻译：用碱性磷脂酰胆碱处理的眼科镜片用于药理学后处理
公开(公告)号：US20120027812A1
公开(公告)日：2012-02-02
申请号：US13148127
申请日：2010-02-08
申请人： Kirsten Eibl-Lindner , Anselm Kampik , Hansjörg Eibl
发明人： Kirsten Eibl-Lindner , Anselm Kampik , Hansjörg Eibl
IPC分类号： A61K31/685 , A61P27/12 , A61P27/02 , C07F9/09 , A61K9/00
CPC分类号： A61L27/54 , A61L31/16 , A61L2300/216 , A61L2300/416 , A61L2430/16
摘要： The invention relates to ophthalmological implants which comprise alkylphosphocholines. Implants of this type may in particular advantageously be used for the prophylaxis of aftercataract.
摘要翻译：本发明涉及包含烷基磷酰胆碱的眼科植入物。这种类型的植入物特别有利地用于预防后药。

8. 发明申请

US20090324704A1 PHOSPHATE DIESTER AMIDES 审中-公开
标题翻译：磷酸二氢钙
公开(公告)号：US20090324704A1
公开(公告)日：2009-12-31
申请号：US12306356
申请日：2007-06-25
申请人： Hansjörg Eibl
发明人： Hansjörg Eibl
IPC分类号： A61K9/127 , C07F9/06
CPC分类号： C07F9/091 , C07F9/222
摘要： The present invention relates to lipid-analogous phosphoric acid compounds and in particular phosphoric triesters, phosphoric diester amides and phosphoric diesters. These are preferably cationic phospholipids preferably having at least one free hydroxyl group.
摘要翻译：本发明涉及脂质 - 类似磷酸化合物，特别是磷酸三酯，磷酸二酯酰胺和磷酸二酯。这些优选为优选具有至少一个游离羟基的阳离子磷脂。

9. 发明授权

US06254879B1 Methods of treating protozoal diseases 有权
标题翻译：治疗原生动物疾病的方法
公开(公告)号：US06254879B1
公开(公告)日：2001-07-03
申请号：US09359405
申请日：1999-07-23
申请人： Hansjörg Eibl , Clemens Unger , Jürgen Engel
发明人： Hansjörg Eibl , Clemens Unger , Jürgen Engel
IPC分类号： A61K600
CPC分类号： A61K31/685 , Y02A50/409 , Y02A50/411 , Y10S514/859 , Y10S514/928 , A61K2300/00
摘要： The invention concerns a new pharmaceutical agent for oral or topical administration in the treatment of protozoal diseases, in particular of leishmaniasis, which contains as the active substance one or several compounds having the general formula I in which R1 is a saturated or monounsaturated or polyunsaturated hydrocarbon residue with 12 to 20 C atoms and R2, R3 and R4 denote independently of one another hydrogen, a C1-C5 alkyl group, a C3-C6 cycloalkyl group or a C1-C5 hydroxyalkyl group whereby two of the residues R2, R3 and R4 can together form a C2-C5 alkylene group which, if desired, can be substituted with an —O—, —S— or NR5 group, in which R5 is hydrogen, a C1-C5 alkyl group, a C3-C6 cycloalkyl group or a C1-C5 hydroxyalkyl group as well as, if desired the usual pharmaceutical auxiliary, diluting, carrier or/and filling substances.
摘要翻译：本发明涉及用于治疗原生动物疾病，特别是利什曼病的新的药物，其含有作为活性物质的一种或几种具有通式Iin的化合物，其中R 1是饱和或不饱和或多不饱和烃残基具有12至20个C原子且R 2，R 3和R 4彼此独立地表示氢，C 1 -C 5烷基，C 3 -C 6环烷基或C 1 -C 5羟烷基，其中残基R 2，R 3和R 4中的两个可以一起形成C 2 -C 5亚烷基，如果需要，其可以被-O - ， - S-或NR 5基团取代，其中R 5是氢，C 1 -C 5烷基，C 3 -C 6环烷基或 C1-C5羟烷基，以及如果需要，通常的药物辅助剂，稀释剂，载体或/和填充物质。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式